Achillion HCV combo has 100% SVR in Phase II

A combination including ACH-3102 from Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) led to 100% SVR8 rates in a Phase II study to treat HCV genotype 1, according to an abstract released ahead of the American Association for the Study of Liver Diseases (AASLD) conference in November.

Twelve treatment-naive patients received 50 mg of ACH-3102, a pan-genotypic second-generation HCV NS5A protein inhibitor, and 400 mg of Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) once daily for eight weeks. Achillion will present results including SVR12 rates at the conference. A second treatment cohort received the same combination regimen for six weeks, with SVR4 data expected by year end. ...